SI2582683T1 - Treatment of gout and hyperuricemia - Google Patents

Treatment of gout and hyperuricemia Download PDF

Info

Publication number
SI2582683T1
SI2582683T1 SI201131474T SI201131474T SI2582683T1 SI 2582683 T1 SI2582683 T1 SI 2582683T1 SI 201131474 T SI201131474 T SI 201131474T SI 201131474 T SI201131474 T SI 201131474T SI 2582683 T1 SI2582683 T1 SI 2582683T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutically acceptable
acceptable salt
use according
allopurinol
alopurinol
Prior art date
Application number
SI201131474T
Other languages
English (en)
Slovenian (sl)
Inventor
Jeffrey Miner
Barry D. Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2582683(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences, Inc. filed Critical Ardea Biosciences, Inc.
Publication of SI2582683T1 publication Critical patent/SI2582683T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201131474T 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia SI2582683T1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia
EP11796324.9A EP2582683B1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
SI2582683T1 true SI2582683T1 (en) 2018-07-31

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131474T SI2582683T1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Country Status (19)

Country Link
US (3) US9216179B2 (cg-RX-API-DMAC7.html)
EP (1) EP2582683B1 (cg-RX-API-DMAC7.html)
JP (1) JP5964821B2 (cg-RX-API-DMAC7.html)
CA (1) CA2802407C (cg-RX-API-DMAC7.html)
CY (1) CY1120473T1 (cg-RX-API-DMAC7.html)
DK (1) DK2582683T3 (cg-RX-API-DMAC7.html)
ES (1) ES2670700T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180780T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038265T2 (cg-RX-API-DMAC7.html)
LT (1) LT2582683T (cg-RX-API-DMAC7.html)
NO (1) NO2019008I1 (cg-RX-API-DMAC7.html)
PL (1) PL2582683T3 (cg-RX-API-DMAC7.html)
PT (1) PT2582683T (cg-RX-API-DMAC7.html)
RS (1) RS57275B1 (cg-RX-API-DMAC7.html)
SI (1) SI2582683T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800266T1 (cg-RX-API-DMAC7.html)
TR (1) TR201806828T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011159732A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300055B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
CN104023723B (zh) * 2011-11-03 2017-05-31 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
WO2021033773A1 (ja) * 2019-08-21 2021-02-25 国立大学法人東京大学 Ａｂｃｃ１１阻害剤
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914611B2 (ja) 2003-12-26 2012-04-11 キッセイ薬品工業株式会社 ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
PT2135608E (pt) 2004-08-25 2012-01-13 Ardea Biosciences Inc S-triazolil-alfa-mercaptoacetanilidas como inibidores de transcritase inversa de vih
CN101646440A (zh) 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
JP2012502049A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135530A2 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
EA020183B1 (ru) 2010-01-08 2014-09-30 Ардеа Биосайнсиз, Инк. Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3-илтио)ацетата натрия и их применение
EP3659601A1 (en) * 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
US8933070B2 (en) * 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
CN106176736A (zh) 2010-10-15 2016-12-07 阿迪亚生命科学公司 用于治疗高尿酸血症及相关疾病的方法
CA2817249C (en) * 2010-12-30 2015-02-10 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
RS56225B1 (sr) 2011-05-24 2017-11-30 Ardea Biosciences Inc Hipertenzija i hiperurikemija

Also Published As

Publication number Publication date
ZA201300055B (en) 2018-05-30
EP2582683A4 (en) 2014-04-30
WO2011159732A1 (en) 2011-12-22
US9216179B2 (en) 2015-12-22
HUE038265T2 (hu) 2018-10-29
EP2582683A1 (en) 2013-04-24
US20160143889A1 (en) 2016-05-26
PT2582683T (pt) 2018-05-25
JP2013528650A (ja) 2013-07-11
CY1120473T1 (el) 2019-07-10
CA2802407C (en) 2018-01-23
ES2670700T3 (es) 2018-05-31
JP5964821B2 (ja) 2016-08-03
HRP20180780T1 (hr) 2018-07-13
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
SMT201800266T1 (it) 2018-07-17
PL2582683T3 (pl) 2018-08-31
CA2802407A1 (en) 2011-12-22
EP2582683B1 (en) 2018-03-21
RS57275B1 (sr) 2018-08-31
NO2019008I1 (no) 2019-02-19
TR201806828T4 (tr) 2018-06-21
US20190015392A1 (en) 2019-01-17
DK2582683T3 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
SI2582683T1 (en) Treatment of gout and hyperuricemia
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
TN2011000446A1 (en) 3h-imidazo [4,5-c]pyridine-6-carboxamides as anti-inflammatory agents
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MX2012007410A (es) Compuestos antivirales novedosos.
CL2012001841A1 (es) Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico.
BR112013017779A2 (pt) derivados de oxazina e seu uso no tratamento de distúrbios neurológicos
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MX2011012122A (es) Derivados de tiofeno.
UA104021C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-b]ПИРИДИНА КАК ИНГИБИТОРЫ РЕПЛИКАЦИИ ВИРУСА
SI2932970T1 (en) Antiviral therapy
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
PE20081578A1 (es) Formulacion en polvo de valganciclovir
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
HRP20120867T1 (hr) Selurampanel
JP2008088189A5 (cg-RX-API-DMAC7.html)
MX2010013978A (es) Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas.
PH12013502381B1 (en) Compounds for adhesion treatment and prevention, compound-related pharmaceutical compositions and methods for the prevention and treatment of adhesions